Harvard Bioscience receives 'notice of allowability' for organism sorting technology.
David Green, President of Harvard Bioscience commented: "We are very pleased to receive this "Notice of Allowability". It confirms the uniqueness of the inventions we have made for high throughput drug discovery. This is only one of several patent applications we have before the USPTO."
Harvard is a global developer, manufacturer and marketer of innovative, enabling tools in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. HBIO sells approximately 10,000 products to thousands of researchers in over 60 countries though its direct sales force, 1,000 page catalog, and through its distributors, the most notable of which is AP Biotech. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany and Belgium with sales facilities in France and Canada.
|Printer friendly Cite/link Email Feedback|
|Comment:||Harvard Bioscience receives 'notice of allowability' for organism sorting technology.|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||Oct 1, 2001|
|Previous Article:||MorphoSys issued patent for HuCAL antibody library.|
|Next Article:||Paradigm Genetics receives herbicide target patent.|